Experimental Weight Loss and Diabetes Drug in Clinical Trials

Diabetes and obesity are closely linked, and plenty of diabetics struggle to follow their doctor's orders to lose weight. The biopharmaceutical company Vivus hopes to promote an investigational new drug, Qnexa, as each a weight loss drug and a diabetes medication.

Qnexa is in section three clinical trials to treat obesity, and in section a pair of clinical development for the treatment of sort a pair of diabetes and sleep apnea. the foremost recent clinical trial of Qnexa as a weight loss drug resulted in a mean ten % weight loss in study participants.

Qnexa may be a combination of the appetite suppressant phentermine, (best referred to as the "phen" in fen-phen, a controversial weight loss drug that was achieved the market in 1997), and also the anticonvulsant topiramate, prescribed to treat epilepsy and stop migraine headaches.

Qnexa was denied approval in late 2010, when the FDA expressed considerations a couple of slightly increased risk of adverse psychiatric and cardiovascular events, and questioned the likelihood of birth defects in pregnant ladies taking the drug.

More than 2400 patients took half within the latest study. Study participants were all clinically obese, and conjointly suffered from 2 or a lot of secondary medical conditions like diabetes or heart disease. Patients conjointly saw enhancements in high blood pressure, cholesterol and A1C levels (glycated hemoglobin). High A1C levels indicate high levels of blood glucose in diabetics.

Shares of Vivus have increased up to sixteen % in worth since the most recent study results were released.  If approved, Qnexa would be the primary new weight loss drug on the market in additional than 10 years. Currently, the sole FDA approved prescription weight loss drug is orlistat (Zenical). Orlistat prevents the body from absorbing the fat in food, and is thought for unpleasant aspect effects like loose, oily stools, fecal incontinence and flatulence.

A second weight-loss drug manufacturer, Orexigen, is additionally struggling to induce FDA approval for his or her new diet drug, Contrave. Contrave may be a combination of bupropion (the antidepressant Wellbutrin, conjointly marketed because the smoking cessation aid Zyban) and naltrexone, an opiate antagonist prescribed to treat narcotic and alcohol addiction. Contrave is meant to curb food cravings, and proved effective than Qnexa in terms of weight loss.

Contrave passed a significant hurdle in late 2010 when an FDA advisory committee voted 13-7 for its approval, however the FDA disagreed in early 2011, soliciting for a brand new clinical trial evaluating the drug's cardiovascular risks.

Arena Pharmaceutical's Lorcaserin was the third diet drug to fail to win FDA approval in 2010, when the FDA deemed that safety considerations outweighed the drug's "marginal effectiveness".

Incoming search terms

diabetes medications,diabetes drug,diabetes medication,long acting insulin,lantus solostar,canadian pharmacy,big mountain medication

Eating Too Quickly Doubles the Risk of Insulin Resistance

Yet another reason to listen to your mother and slow down and chew your food properly - eating too quickly has been associated with a doubled risk of developing impaired glucose tolerance, or pre-diabetes. As the name suggests, pre-diabetes is the forerunner to developing type 2 diabetes. Most diabetics have type 2 diabetes – a form of diabetes where your body no longer responds properly to insulin (called insulin resistance). Type 2 diabetes used to be described as non insulin dependent diabetes.

Insulin is the hormone that moves sugar (glucose) from the blood to the body's cells to provide them with energy. If your cells do not use insulin properly, the pancreas produces more insulin that normal to cope with the body's demands. Eventually, the pancreas cannot keep up, and excess glucose builds up in the bloodstream. Type 2 diabetes is characterized by high levels of glucose in the blood.

A recent Japanese study followed over 170 healthy individuals for three years, monitoring their eating habits. Snacking, eating late at night, skipping meals and eating out were not associated with developing pre-diabetes. The one and only eating habit associated with the development of insulin resistance was eating too quickly.

The researchers aren't sure why eating faster makes an individual more likely to develop pre-diabetes and type 2 diabetes, but suspect that eating rapidly results in higher post-meal blood glucose levels.  Some doctors also point out that eating too quickly results in an overall increase in the amount of calories taken in, and a resulting weight gain. Since it takes about 20 minutes for the brain to receive the signal that the stomach is full, those who eat quickly continue eating without realizing that their stomach is filled.

Previous research has also shown that eating quickly results in increased weight gain. Insulin resistance generally increases with increased body fat, and there is a pronounced connection between obesity and diabetes. The two are so closely connected that it gave rise to the term "diabesity". Diabesity is currently epidemic across the developed world.

Insulin resistance has no symptoms. Pre-diabetes is sometimes called impaired glucose tolerance, and can be diagnosed with a fasting glucose test or a glucose tolerance test. The American Diabetes Association recommends that adults who are overweight and have one or more additional risk factors for diabetes should consider being tested. Additional risk factors include:

• Having a parent or sibling with diabetes
• Being physically inactive.
• Being African American,Alaskanative, American Indian, Asian American, Hispanic or Latino, or a Pacific Islander
• Giving birth to a baby weighing more than 9 pounds or being diagnosed with gestational diabetes
• Having high blood pressure or being treated for high blood pressure
• Low HDL ("good") cholesterol levels or high triglyceride levels
• Having polycystic ovary syndrome
• Having a history of cardiovascular disease

People with pre-diabetes can avoid becoming diabetic and having to take diabetes medication by losing weight, being physically active, eating a healthy diet, and, as we now know, not eating too quickly.

Incoming search terms

insulin resistance,insulin dependent,diabetes medication,long acting insulin,big mountain drugs,canadian pharmacy,buy lantus,lantus solostar

Experimental Weight Loss and Diabetes Drug in Clinical Trials

Diabetes and obesity are closely linked, and lots of diabetics struggle to follow their doctor's orders to lose weight. The biopharmaceutical company Vivus hopes to plug an investigational new drug, Qnexa, as each a weight loss drug and a diabetes medication.

Qnexa is in section three clinical trials to treat obesity, and in section a pair of clinical development for the treatment of sort a pair of diabetes and sleep apnea. the foremost recent clinical trial of Qnexa as a weight loss drug resulted in a mean ten p.c weight loss in study participants.

Qnexa may be a combination of the appetite suppressant phentermine, (best referred to as the "phen" in fen-phen, a controversial weight loss drug that was done the market in 1997), and therefore the anticonvulsant topiramate, prescribed to treat epilepsy and stop migraine headaches.

Qnexa was denied approval in late 2010, when the FDA expressed issues a couple of slightly increased risk of adverse psychiatric and cardiovascular events, and questioned the chance of birth defects in pregnant girls taking the drug.

More than 2400 patients took half within the latest study. Study participants were all clinically obese, and conjointly suffered from 2 or a lot of secondary medical conditions like diabetes or heart disease. Patients conjointly saw enhancements in high blood pressure, cholesterol and A1C levels (glycated hemoglobin). High A1C levels indicate high levels of blood glucose in diabetics.

Shares of Vivus have increased up to sixteen p.c in price since the most recent study results were released.  If approved, Qnexa would be the primary new weight loss drug on the market in additional than 10 years. Currently, the sole FDA approved prescription weight loss drug is orlistat (Zenical). Orlistat prevents the body from absorbing the fat in food, and is understood for unpleasant aspect effects like loose, oily stools, fecal incontinence and flatulence.

A second weight-loss drug manufacturer, Orexigen, is additionally struggling to induce FDA approval for his or her new diet drug, Contrave. Contrave may be a combination of bupropion (the antidepressant Wellbutrin, conjointly marketed because the smoking cessation aid Zyban) and naltrexone, an opiate antagonist prescribed to treat narcotic and alcohol addiction. Contrave is intended to curb food cravings, and proved effective than Qnexa in terms of weight loss.

Contrave passed a significant hurdle in late 2010 when an FDA advisory committee voted 13-7 for its approval, however the FDA disagreed in early 2011, requesting a replacement clinical trial evaluating the drug's cardiovascular risks.

Arena Pharmaceutical's Lorcaserin was the third diet drug to fail to win FDA approval in 2010, when the FDA deemed that safety issues outweighed the drug's "marginal effectiveness".

Incoming search terms

diabetes medications,diabetes drug,diabetes medication,long acting insulin,lantus solostar,canadian pharmacy,big mountain medication

Experimental Weight Loss and Diabetes Drug in Clinical Trials

Diabetes and obesity are closely linked, and plenty of diabetics struggle to follow their doctor's orders to lose weight. The biopharmaceutical company Vivus hopes to promote an investigational new drug, Qnexa, as each a weight loss drug and a diabetes medication.

 

Qnexa is in part three clinical trials to treat obesity, and in part a pair of clinical development for the treatment of kind a pair of diabetes and sleep apnea. the foremost recent clinical trial of Qnexa as a weight loss drug resulted in a mean ten p.c weight loss in study participants.

 

Qnexa may be a combination of the appetite suppressant phentermine, (best called the "phen" in fen-phen, a controversial weight loss drug that was attained the market in 1997), and also the anticonvulsant topiramate, prescribed to treat epilepsy and stop migraine headaches.

 

Qnexa was denied approval in late 2010, when the FDA expressed issues a couple of slightly increased risk of adverse psychiatric and cardiovascular events, and questioned the chance of birth defects in pregnant ladies taking the drug.

 

More than 2400 patients took half within the latest study. Study participants were all clinically obese, and conjointly suffered from 2 or a lot of secondary medical conditions like diabetes or heart disease. Patients conjointly saw enhancements in high blood pressure, cholesterol and A1C levels (glycated hemoglobin). High A1C levels indicate high levels of blood glucose in diabetics.

 

Shares of Vivus have increased up to sixteen p.c in worth since the most recent study results were released.  If approved, Qnexa would be the primary new weight loss drug on the market in additional than 10 years. Currently, the sole FDA approved prescription weight loss drug is orlistat (Zenical). Orlistat prevents the body from absorbing the fat in food, and is understood for unpleasant facet effects like loose, oily stools, fecal incontinence and flatulence.

 

A second weight-loss drug manufacturer, Orexigen, is additionally struggling to induce FDA approval for his or her new diet drug, Contrave. Contrave may be a combination of bupropion (the antidepressant Wellbutrin, conjointly marketed because the smoking cessation aid Zyban) and naltrexone, an opiate antagonist prescribed to treat narcotic and alcohol addiction. Contrave is intended to curb food cravings, and proved effective than Qnexa in terms of weight loss.

 

Contrave passed a significant hurdle in late 2010 when an FDA advisory committee voted 13-7 for its approval, however the FDA disagreed in early 2011, requesting a brand new clinical trial evaluating the drug's cardiovascular risks.

 

Arena Pharmaceutical's Lorcaserin was the third diet drug to fail to win FDA approval in 2010, when the FDA deemed that safety issues outweighed the drug's "marginal effectiveness".

Incoming search terms

diabetes medications,diabetes drug,diabetes medication,long acting insulin,lantus solostar,canadian pharmacy,big mountain medicine

Experimental Weight Loss and Diabetes Drug in Clinical Trials

Diabetes and obesity are closely linked, and many diabetics struggle to follow their doctor's orders to lose weight. The biopharmaceutical company Vivus hopes to market an investigational new drug, Qnexa, as both a weight loss drug and a diabetes medication.

Qnexa is in phase 3 clinical trials to treat obesity, and in phase 2 clinical development for the treatment of type 2 diabetes and sleep apnea. The most recent clinical trial of Qnexa as a weight loss drug resulted in an average 10 percent weight loss in study participants.

Qnexa is a combination of the appetite suppressant phentermine, (best known as the "phen" in fen-phen, a controversial weight loss drug that was pulled off the market in 1997), and the anticonvulsant topiramate, prescribed to treat epilepsy and prevent migraine headaches.

Qnexa was denied approval in late 2010, when the FDA expressed concerns about a slightly increased risk of adverse psychiatric and cardiovascular events, and questioned the possibility of birth defects in pregnant women taking the drug.

More than 2400 patients took part in the latest study. Study participants were all clinically obese, and also suffered from two or more secondary medical conditions such as diabetes or heart disease. Patients also saw improvements in high blood pressure, cholesterol and A1C levels (glycated hemoglobin). High A1C levels indicate high levels of blood glucose in diabetics.

Shares of Vivus have increased up to sixteen percent in value since the latest study results were released. If approved, Qnexa would be the first new weight loss drug on the market in more than ten years. Currently, the only FDA approved prescription weight loss drug is orlistat (Zenical). Orlistat prevents the body from absorbing the fat in food, and is known for unpleasant side effects such as loose, oily stools, fecal incontinence and flatulence.

A second weight-loss drug manufacturer, Orexigen, is also struggling to get FDA approval for their new diet drug, Contrave. Contrave is a combination of bupropion (the antidepressant Wellbutrin, also marketed as the smoking cessation aid Zyban) and naltrexone, an opiate antagonist prescribed to treat narcotic and alcohol addiction. Contrave is designed to curb food cravings, and proved effective than Qnexa in terms of weight loss.

Contrave passed a major hurdle in late 2010 when an FDA advisory committee voted 13-7 for its approval, but the FDA disagreed in early 2011, asking for a new clinical trial evaluating the drug's cardiovascular risks.

Arena Pharmaceutical's Lorcaserin was the third diet drug to fail to win FDA approval in 2010, when the FDA deemed that safety concerns outweighed the drug's "marginal effectiveness".

Incoming search terms


diabetes medications,diabetes drug,diabetes medication,long acting insulin,lantus solostar,canadian pharmacy,big mountain drugs